Developer docs
API playgroundTry for free, no card

Search company profiles

SR One

Full company profile

uuid00000wc

Namestring
SR One
Legal namestring
SR One Capital Management, LP
Websiteurl
srone.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

SR One is an independent biotechnology venture capital firm that was spun out from GlaxoSmithKline in November 2020, originally founded in 1985 as GSK's corporate venture arm. The firm invests across stages (seed/Series A through crossover and post-IPO) in biotech companies developing innovative science into medicines, with a stated "back-and-build" approach focused on companies with strong fundamentals, clearly defined development pathways, and novel disease approaches. Its portfolio spans 50+ companies across therapeutic areas including oncology, fibrosis, respiratory, dermatology, gene therapy, and obesity, with historical exits including MyoKardia ($13.1B to BMS), Turning Point Therapeutics ($4.1B to BMS), Principia Biopharma ($3.7B to Sanofi), and Audentes ($3B to Astellas).

The firm operates from two offices — Redwood City, California and London, UK — providing transatlantic access to the two largest Western biotech ecosystems. It has raised $500M for Fund I at spin-out and $600M for Fund II in March 2023, totaling approximately $1.1B in committed capital. The team is small (11-50 employees) and structured around core investing personnel (CEO, COO/Managing Partner, Partners, Principals, Associates), a venture partner network, and three formal operating partners dedicated to portfolio value creation, capital raising, and business development. The firm is registered with the US SEC as an investment adviser (SR One Capital Management, LP, Delaware) and its UK affiliate (SR One Capital LLP) is an appointed representative of Langham Hall Fund Management LLP, authorized and regulated by the Financial Conduct Authority.

Revenue is generated through traditional VC mechanics: management fees on committed capital (typically 1.5-2.5% annually) and carried interest on fund returns from successful portfolio exits. Fund terms and LP identities are privately negotiated and not publicly disclosed. Distribution of capital occurs via direct equity investments into portfolio companies, sourced through the firm's transatlantic presence and industry network, with deal activity spanning lead and co-lead roles in rounds ranging from Series A through post-IPO follow-on offerings.

Short descriptiontext

SR One is an independent biotechnology venture capital firm, spun out from GlaxoSmithKline in 2020, that invests across stages in biotech companies translating innovative science into medicines. Operating transatlantically from Redwood City and London, it manages $1.1B across two funds.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biotechnology venture capital, life sciences investment, biotech funding rounds, venture capital services, healthcare venture funding
Industry2 codes
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
NAICS code1 code
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Biotechnology Venture Capital
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Investment Returns (Carried Interest)
TypeLicensing Royalties
Description

SR One generates returns through successful portfolio company exits via IPOs and acquisitions, with carried interest on fund returns. Notable exits include Princiia Biopharma (acquired by Sanofi for $3.7B), Turning Point Therapeutics (acquired by Bristol Myers Squibb for $4.1B), MyoKardia (acquired by Bristol Myers Squibb for $13.1B), Audentes Therapeutics (acquired by Astellas for $3B), and others.

srone.com
2Management Fees
TypeSubscription Recurring
Description

VC firms typically charge management fees on committed capital under management. SR One raised an initial $500M at spinout from GSK in 2020 and closed Fund II at $600M.

srone.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

SR One is an independent biotechnology venture capital firm that invests capital and provides strategic partnership and operational support to early and late-stage biotech companies developing innovative medicines. The firm manages dedicated venture funds (Fund I at $500M raised at 2020 GSK spinout and Fund II at $600M closed in 2023) and takes a 'back-and-build' approach focused on companies with strong fundamentals, defined development pathways, and novel disease approaches.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

SR One is a biotechnology venture capital firm that provides investment capital and strategic partnership services to early and late-stage biotech companies. Rather than developing and commercializing its own therapeutic products, SR One serves as a financial partner to founders and entrepreneurs working to translate innovative science into medicines. The firm takes a back-and-build approach to investments, focusing on companies with strong underlying fundamentals, clearly defined development pathways, and novel approaches to addressing diseases. SR One does not offer standalone software products or technology platforms; its offering consists of venture capital investment, operational expertise, and strategic guidance to its portfolio companies.

Product and service3 records
1SR One Fund I
CategoryVenture capital fund
Description

SR One's first independent venture fund of $500M raised at the firm's spinout from GlaxoSmithKline in November 2020, deployed across early- and late-stage biotech equity investments in companies with strong fundamentals, defined development pathways, and novel disease approaches. Available for limited partner commitments from institutional investors.

2SR One Fund II
CategoryVenture capital fund
Description

SR One's second venture fund of $600M closed in March 2023, continuing the firm's transatlantic biotech investment strategy across early- and late-stage companies developing novel therapeutics. Available for limited partner commitments from institutional investors.

3Strategic Partnership and Operational Support to Portfolio Companies
CategoryInvestment advisory and operational services
Description

Operating Partners and the investing team deliver portfolio value creation, capital raising, and business development support to biotech portfolio companies across the firm's transatlantic footprint, supplementing capital with operational expertise and geographic reach. Targeted at founders and management teams of biotech companies in the SR One portfolio.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1S.R. One International B.V.
Strategic tierCoreTypeOthersAnnounced on2026-04-06
Description

GSK Pakistan operates as a subsidiary of S.R. One International B.V. incorporated in the Netherlands, with GlaxoSmithKline plc in the United Kingdom as its ultimate parent company. This is the legacy corporate structure from which SR One Capital Management was spun out.

brecorder.com
Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-09-22
Description

Wilson Sonsini advised SR One on Avenzo Therapeutics' $60 million Series B funding round, representing legal counsel support for portfolio company investments.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Atlas Venture is a leading biotech-focused early-stage venture firm that builds and funds therapeutic companies, often from inception. It is the closest comparable to SR One in fund size, healthcare-only mandate, and cross-Atlantic presence (Boston and London), making it SR One's most direct peer.

TypeDirect peer
Description

ARCH is a long-standing biotech VC investing across therapeutic platforms with multi-billion-dollar follow-on funds. SR One competes with ARCH for Series A and later-stage therapeutic rounds and shares a deep-science, crossover-tolerating investment style.

TypeDirect peer
Description

OrbiMed is one of the largest dedicated healthcare investors globally, deploying across stages from venture through public markets. SR One has co-invested with OrbiMed on rounds such as Windward Bio, making it a frequent peer and occasional co-investor in biotech financings.

TypeDirect peer
Description

Frazier Life Sciences is a healthcare-dedicated VC investing across public and private biotech. SR One has co-invested with Frazier on Immutrin and AirNexis, reflecting closely overlapping theses in clinical-stage biotech.

TypeDirect peer
Description

Versant is a healthcare-only venture firm with offices in North America and Europe and a track record of company creation in biotech. Its stage breadth and transatlantic footprint put it in direct competition with SR One for therapeutic financings.

TypeBroad incumbent
Description

NEA is a multi-stage generalist firm with a deep healthcare practice and prior employer of several SR One team members including Jake Nunn and Sasha Keough. It is a broader peer that overlaps with SR One in biotech venture and crossover rounds.

TypeDirect peer
Description

RA Capital is a healthcare-focused crossover and venture investor active from Series A through public markets. SR One has co-invested with RA on Corxel Pharmaceuticals, Poplar Therapeutics, and other deals, indicating close peer overlap in biotech financings.

TypeDirect peer
Description

5AM is an early-stage biotech venture firm financing transformative life-science companies. It overlaps with SR One in seed-to-Series A therapeutic company creation, although it operates at a smaller scale.

TypeBroad incumbent
Description

Venrock is a long-tenured multi-stage VC with a sizable healthcare practice that invests from Series A onward in biotech. It is comparable to SR One in therapeutic investing but operates a broader, generalist fund structure.

TypeEmerging player
Description

Sanofi Ventures is the corporate venture arm of Sanofi that invests in early-stage biotech relevant to Sanofi's therapeutic strategy. As a CVC with similar biotech-stage focus, it is a comparable emerging player to SR One's heritage as a GSK venture spinoff.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment234 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SR One

Biotechnology Venture Capitalsrone.com

SR One is an independent biotechnology venture capital firm, spun out from GlaxoSmithKline in 2020, that invests across stages in biotech companies translating innovative science into medicines. Operating transatlantically from Redwood City and London, it manages $1.1B across two funds.

What SR One does

SR One is an independent biotechnology venture capital firm that was spun out from GlaxoSmithKline in November 2020, originally founded in 1985 as GSK's corporate venture arm. The firm invests across stages (seed/Series A through crossover and post-IPO) in biotech companies developing innovative science into medicines, with a stated "back-and-build" approach focused on companies with strong fundamentals, clearly defined development pathways, and novel disease approaches. Its portfolio spans 50+ companies across therapeutic areas including oncology, fibrosis, respiratory, dermatology, gene therapy, and obesity, with historical exits including MyoKardia ($13.1B to BMS), Turning Point Therapeutics ($4.1B to BMS), Principia Biopharma ($3.7B to Sanofi), and Audentes ($3B to Astellas).

The firm operates from two offices — Redwood City, California and London, UK — providing transatlantic access to the two largest Western biotech ecosystems. It has raised $500M for Fund I at spin-out and $600M for Fund II in March 2023, totaling approximately $1.1B in committed capital. The team is small (11-50 employees) and structured around core investing personnel (CEO, COO/Managing Partner, Partners, Principals, Associates), a venture partner network, and three formal operating partners dedicated to portfolio value creation, capital raising, and business development. The firm is registered with the US SEC as an investment adviser (SR One Capital Management, LP, Delaware) and its UK affiliate (SR One Capital LLP) is an appointed representative of Langham Hall Fund Management LLP, authorized and regulated by the Financial Conduct Authority.

Revenue is generated through traditional VC mechanics: management fees on committed capital (typically 1.5-2.5% annually) and carried interest on fund returns from successful portfolio exits. Fund terms and LP identities are privately negotiated and not publicly disclosed. Distribution of capital occurs via direct equity investments into portfolio companies, sourced through the firm's transatlantic presence and industry network, with deal activity spanning lead and co-lead roles in rounds ranging from Series A through post-IPO follow-on offerings.

SR One firmographics

Firmographics
Name
SR One
Legal name
SR One Capital Management, LP
Website
https://srone.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
SR One is an independent biotechnology venture capital firm, spun out from GlaxoSmithKline in 2020, that invests across stages in biotech companies translating innovative science into medicines. Operating transatlantically from Redwood City and London, it manages $1.1B across two funds.
Ownership category
akta.pro rank

SR One industry classification

Industry
Product category
Biotechnology Venture Capital
NAICS
Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSANAAAB
Early-Stage Venture Capital (Series A/B)

Keywords

  • Biotechnology venture capital
  • Life sciences investment
  • Biotech funding rounds
  • Venture capital services
  • Healthcare venture funding

Where SR One is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

SR One business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Investment Returns (Carried Interest): SR One generates returns through successful portfolio company exits via IPOs and acquisitions, with carried interest on fund returns. Notable exits include Princiia Biopharma (acquired by Sanofi for $3.7B), Turning Point Therapeutics (acquired by Bristol Myers Squibb for $4.1B), MyoKardia (acquired by Bristol Myers Squibb for $13.1B), Audentes Therapeutics (acquired by Astellas for $3B), and others.
  2. Management Fees: VC firms typically charge management fees on committed capital under management. SR One raised an initial $500M at spinout from GSK in 2020 and closed Fund II at $600M.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

SR One product offering

Product offering

Core offering

SR One is an independent biotechnology venture capital firm that invests capital and provides strategic partnership and operational support to early and late-stage biotech companies developing innovative medicines. The firm manages dedicated venture funds (Fund I at $500M raised at 2020 GSK spinout and Fund II at $600M closed in 2023) and takes a 'back-and-build' approach focused on companies with strong fundamentals, defined development pathways, and novel disease approaches.

Product overview

SR One is a biotechnology venture capital firm that provides investment capital and strategic partnership services to early and late-stage biotech companies. Rather than developing and commercializing its own therapeutic products, SR One serves as a financial partner to founders and entrepreneurs working to translate innovative science into medicines. The firm takes a back-and-build approach to investments, focusing on companies with strong underlying fundamentals, clearly defined development pathways, and novel approaches to addressing diseases. SR One does not offer standalone software products or technology platforms; its offering consists of venture capital investment, operational expertise, and strategic guidance to its portfolio companies.

Differentiator

Problem solved

Functional benefit

Products and services

  • SR One Fund I SR One's first independent venture fund of $500M raised at the firm's spinout from GlaxoSmithKline in November 2020, deployed across early- and late-stage biotech equity investments in companies with strong fundamentals, defined development pathways, and novel disease approaches. Available for limited partner commitments from institutional investors.
  • SR One Fund II SR One's second venture fund of $600M closed in March 2023, continuing the firm's transatlantic biotech investment strategy across early- and late-stage companies developing novel therapeutics. Available for limited partner commitments from institutional investors.
  • Strategic Partnership and Operational Support to Portfolio Companies Operating Partners and the investing team deliver portfolio value creation, capital raising, and business development support to biotech portfolio companies across the firm's transatlantic footprint, supplementing capital with operational expertise and geographic reach. Targeted at founders and management teams of biotech companies in the SR One portfolio.

Companies that use SR One

Customer profile

Segments2 records

Ideal customer profiles2 records

SR One technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

SR One partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • S.R. One International B.V.coreOthers · 6 April 2026GSK Pakistan operates as a subsidiary of S.R. One International B.V. incorporated in the Netherlands, with GlaxoSmithKline plc in the United Kingdom as its ultimate parent company. This is the legacy corporate structure from which SR One Capital Management was spun out.
  • Wilson Sonsini Goodrich & RosatiminorImplementation/ SI/ Consulting Partner · 22 September 2025Wilson Sonsini advised SR One on Avenzo Therapeutics' $60 million Series B funding round, representing legal counsel support for portfolio company investments.

Scale indicators3 records

Recent moves8 records

Expansion highlights5 records

SR One competitors and assessment

Company assessment

Direct peers

  • Atlas Venture: Atlas Venture is a leading biotech-focused early-stage venture firm that builds and funds therapeutic companies, often from inception. It is the closest comparable to SR One in fund size, healthcare-only mandate, and cross-Atlantic presence (Boston and London), making it SR One's most direct peer.
  • ARCH Venture Partners: ARCH is a long-standing biotech VC investing across therapeutic platforms with multi-billion-dollar follow-on funds. SR One competes with ARCH for Series A and later-stage therapeutic rounds and shares a deep-science, crossover-tolerating investment style.
  • OrbiMed: OrbiMed is one of the largest dedicated healthcare investors globally, deploying across stages from venture through public markets. SR One has co-invested with OrbiMed on rounds such as Windward Bio, making it a frequent peer and occasional co-investor in biotech financings.
  • Frazier Life Sciences: Frazier Life Sciences is a healthcare-dedicated VC investing across public and private biotech. SR One has co-invested with Frazier on Immutrin and AirNexis, reflecting closely overlapping theses in clinical-stage biotech.
  • Versant Ventures: Versant is a healthcare-only venture firm with offices in North America and Europe and a track record of company creation in biotech. Its stage breadth and transatlantic footprint put it in direct competition with SR One for therapeutic financings.
  • RA Capital Management: RA Capital is a healthcare-focused crossover and venture investor active from Series A through public markets. SR One has co-invested with RA on Corxel Pharmaceuticals, Poplar Therapeutics, and other deals, indicating close peer overlap in biotech financings.
  • 5AM Ventures: 5AM is an early-stage biotech venture firm financing transformative life-science companies. It overlaps with SR One in seed-to-Series A therapeutic company creation, although it operates at a smaller scale.

Broad incumbents

  • New Enterprise Associates (NEA): NEA is a multi-stage generalist firm with a deep healthcare practice and prior employer of several SR One team members including Jake Nunn and Sasha Keough. It is a broader peer that overlaps with SR One in biotech venture and crossover rounds.
  • Venrock: Venrock is a long-tenured multi-stage VC with a sizable healthcare practice that invests from Series A onward in biotech. It is comparable to SR One in therapeutic investing but operates a broader, generalist fund structure.

Emerging players

  • Sanofi Ventures: Sanofi Ventures is the corporate venture arm of Sanofi that invests in early-stage biotech relevant to Sanofi's therapeutic strategy. As a CVC with similar biotech-stage focus, it is a comparable emerging player to SR One's heritage as a GSK venture spinoff.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

SR One social profiles

Digital presence

SR One compliance and trust

Trust signal

Compliance1 record

SR One financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SR One leadership team

Management profile

Number of profiles

Profiles12 records

SR One funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SR One M&A and investment

M&A and investment

M&A

Investments234 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SR One

What does SR One do?

SR One is an independent biotechnology venture capital firm that invests capital and provides strategic partnership and operational support to early and late-stage biotech companies developing innovative medicines. The firm manages dedicated venture funds (Fund I at $500M raised at 2020 GSK spinout and Fund II at $600M closed in 2023) and takes a 'back-and-build' approach focused on companies with strong fundamentals, defined development pathways, and novel disease approaches.

Is SR One a public or private company?

SR One is a private company. It is classified as management employee owned and is currently operating.

When was SR One founded?

SR One was founded in 2020. It employs 11 to 50 people.

Where is SR One based?

SR One is headquartered in San Francisco, United States, in the North America region.

How does SR One make money?

Two revenue lines are on record. Investment Returns (Carried Interest) is the primary driver. The others are management Fees.

Who are SR One's main competitors?

Direct peers on record are Atlas Venture, ARCH Venture Partners, OrbiMed, Frazier Life Sciences, Versant Ventures, RA Capital Management and 5AM Ventures. Broad incumbents are New Enterprise Associates (NEA) and Venrock. Sanofi Ventures is listed as an emerging player.

Does SR One have an API?

No public API is recorded for SR One.

What industry is SR One in?

SR One's product category is Biotechnology Venture Capital. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of FSANAAAB, Early-Stage Venture Capital (Series A/B). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Ticker ReportSR One bought 1.6 million ADARx sharesSR One Capital Management, a 10% owner, bought 1.6 million ADARx shares on September 28, 2026, at $17 each, costing about $27.2 million. The filing also recorded IPO-related preferred-stock conversions without further payment. The post-trade holding of 592,593 shares sets a baseline for future filings.American Banking and Market NewsADARx Pharmaceuticals (NASDAQ:ADRX) Stock: Insider Sr One Capital Management, Llc Buys 1,600,000 SharesSr One Capital Management, Llc bought 1,600,000 ADARx Pharmaceuticals shares at $17.00 each on September 28th, totaling $27.2 million. The purchase raised the insider's direct ownership to 5,554,094 shares, a 40.46% increase. The company is a clinical-stage biopharmaceutical focused on RNA-based medicines.Ticker ReportADARx Pharmaceuticals (NASDAQ:ADRX) Major Shareholder Acquires 1,600,000 Shares of Company StockSr One Capital Management, a major shareholder of ADARx Pharmaceuticals, purchased 1,600,000 shares on September 28th at an average cost of $17.00 per share, totaling $27.2 million. The acquisition increased the shareholder's ownership by 40.46%, and the company's stock rose 2.7% to $20.64 on Tuesday.Venture Capital Access OnlineCrystalys Therapeutics Announces $130 Million Series B Financing to Advance Global Phase 3 Development and Commercialization of Dotinurad for GoutCrystalys Therapeutics closed a $130 million Series B financing led by Frazier Life Sciences to advance dotinurad, a once-daily oral URAT1 inhibitor for gout. The proceeds will support ongoing Phase 3 trials RUBY and TOPAZ and commercialization preparation. The company aims to bring a second-line treatment option to patients failing first-line therapies.FinSMEsCrystalys Therapeutics Raises $130M in Series B FundingCrystalys Therapeutics raised $130M in Series B funding led by Frazier Life Sciences. The company will use the funds for late-stage clinical development and commercialization preparation of dotinurad, a once-daily oral URAT1 inhibitor for gout. The lead candidate is in clinical development as a second-line therapy.Venture Capital Access OnlineFORE Biotherapeutics Announces Closing of Upsized $67.4 Million Series D-2 Extension Financing and Highlights Recent Plixorafenib AchievementsFORE Biotherapeutics closed an upsized $67.4 million Series D-2 extension financing, bringing total Series D-2 to $110 million. The funds will support late-stage development of plixorafenib, with topline data from the FORTE study's BRAF V600E CNS tumor basket anticipated around the end of 2026. The company also announced protocol improvements, including enrollment of patients as young as 8 years old.BioSpaceAntag Therapeutics Elects Keith Leonard as Chairman of its Board of DirectorsAntag Therapeutics elected Keith Leonard as chairman of its board of directors. The company plans to initiate Phase 2a trials of its GIPR antagonist AT7687 in mid-2026, following a successful Phase 1 trial. Leonard previously led Unity Biotechnology and Kythera Biopharmaceuticals.BioSpaceAntag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonistAntag Therapeutics presented Phase 1 data for AT7687, a GIPR antagonist, at the 2026 ADA Scientific Sessions, showing favorable safety and tolerability with no GI signals. Preclinical combination with cagrilintide in NHPs yielded 12.2% weight loss versus 7.8% with cagrilintide alone. A Phase 2a trial is expected to start in mid-2026.BioSpaceRallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private PlacementRallybio and Avenzo announced a merger agreement to combine into Avenzo Therapeutics, trading as AVZO on Nasdaq. A concurrent oversubscribed private placement of $215 million will fund operations into late 2028. The deal is expected to close in Q4 2026, subject to stockholder approvals and SEC registration.GenengnewsAttacking Gout: Crystalys Sees Room for Its Dotinurad and Other Allopurinol AlternativesCrystalys Therapeutics dosed the first patient with its gout drug dotinurad in Phase II AMETHYST trial, targeting patients intolerant to allopurinol. Sobi's pozdeutinurad met its Phase III primary endpoint, with 69.2% of patients achieving serum uric acid <6 mg/dL at month 6. Crystalys plans Phase III trials RUBY and TOPAZ, expecting to position dotinurad as a second-line treatment.